Medtronic self-expanding tavr platform shows excellent longer-term performance at five years in surtavi trial

Tct 2021: intermediate risk tavr patients demonstrate strong hemodynamics and stable valve performance at five years dublin and orlando, fla., nov. 5, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today unveiled five-year clinical data from the surgical replacement and transcatheter aortic valve implantation (surtavi) trial, which was presented as a late breaking clinical trial at the 33rd transcatheter cardiovascular therapeutics (tct) conference, the annual scientific symposium of the cardiovascular research foundation.
MDT Ratings Summary
MDT Quant Ranking